Dermapharm Holding SE
DMPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $3 | $3 | $3 | $2 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 2.6% | 12.3% | 8.7% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 65% | 61.2% | 64.5% | 65.8% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 27.2% | 22.8% | 31.6% | 37.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 9.6% | 5.4% | 13.1% | 22.2% |
| EPS Diluted | 2.11 | 1.16 | 2.49 | 3.89 |
| % Growth | 81.9% | -53.4% | -36% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |